Ketorolac tris salt (C09-0930-084)

Ketorolac (tromethamine salt) inhibits both isoforms of Cox in recombinant rat and human enzyme systems. Ketorolac inhibits rat Cox-1 (IC50 of 0.27 μM), rat Cox-2 (IC50 of 2.06 μM), human Cox-1 (IC50 of 1.23 μM) and human Cox-2 (IC50 of 3.50 μM). The (S) enantiomer of Ketorolac with rat Cox-1 (IC50 of 0.10 μM) is approximately twice as potent as the racemate, whereas the (R)-enantiomer (IC50 of > 100 μM) is virtually without activity. Ketorolac shows inhibition of eicosanoid formation in HEL cells (Cox-1, IC50 of 0.025 μM) and LPS-stimulated Mono Mac 6 cells (Cox-2, IC50 of 0.039 μM), but does not significantly inhibit NO accumulation in supernatants of LPS-stimulated RAW 264.7 cells up to 300 μM. Ketorolac significantly inhibits thymidine incorporation of human osteoblasts (hOBs) upon 24 hours treatment in a dose-dependent manner, and inhibits proliferation and arrests cell cycle at G0/G1 phase in hOBs.A non selective inhibitior of Cox-1 and Cox-2. Specification: ≥99% MDL Number: MFCD00887595 Molecular Formula: C19H24N2O6 Molecular Weight: 376.4 PubChem CID: 84003 Isomeric SMILES: C1CN2C(=CC=C2C(=O)C3=CC=CC=C3)C1C(=O)O.C(C(CO)(CO)N)O Related Documents: https://ald-pub-files.oss-cn-shanghai.aliyuncs.com/aladdinsci/pdp/sds/1/K129289-SCI_8b14b66a37429667c244af1b82db1ac9.pdf